WallStSmart

Cerus Corporation (CERS)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 9588% more annual revenue ($20.98B vs $216.56M). GEHC leads profitability with a 9.1% profit margin vs -4.4%. GEHC earns a higher WallStSmart Score of 57/100 (C).

CERS

Avoid

31

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -5.79

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CERS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
24.1%8/10

Revenue surging 24.1% year-over-year

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CERS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$559.03M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.443/10

Elevated debt levels

Return on EquityProfitability
-14.1%2/10

ROE of -14.1% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CERS

The strongest argument for CERS centers on Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CERS

The primary concerns for CERS are EPS Growth, Market Cap, Debt/Equity.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CERS profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

CERS carries more volatility with a beta of 1.77 — expect wider price swings.

CERS is growing revenue faster at 24.1% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cerus Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?